SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

Patients with moderate to severe HS experienced sustained symptomatic and quality-of-life improvements with the monoclonal ...

Boehringer Ingelheim has been awarded a multi-year contract to continue to provide antigen and vaccine supply capability as ...

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...

Washington, D.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Today, the New Civil Liberties Alliance filed an amicus curiae brief with the U.S. Court of Appeals for the Second Circuit in Boehringer Ingelheim ...

Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...

No. 49 / 2024 Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a solid financial ...

Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity.

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

Junior Professor Johannes Walker, University of Göttingen, has been awarded an Exploration Grant from the Boehringer Ingelheim Foundation. Walker teaches and carries out research at the Institute for ...

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

Kikuchi–Fujimoto disease (KFD), histiocytic necrotising lymphadenitis, is a benign and self-limiting disease characterised ...